ArticleEuropean journal of medical research2025
Identification of the pyroptosis, apoptosis, and necroptosis (PANoptosis) involved in osteogenic differentiation inhibition impaired by tumor necrosis factor-α.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Reprogramming bone homeostasis: The recoupling-oriented framework of bidirectional regulation strategies for osteoporosis.iScience · 2026Review
- PANoptosis nexus in ischemia-reperfusion injury: from integrated cell death mechanisms to novel therapeutic opportunities.Frontiers in immunology · 2026Review
- Inflammasome-associated pyroptosis and tumor angiogenesis in prostate cancer.Iranian journal of basic medical sciences · 2026Review
- Programmed cell death in degenerative skeletal diseases: molecular crosstalk and combinatorial therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
- HIF-1α at the intersection of hypoxia, ferroptosis-associated stress, and cell death crosstalk in osteomyelitis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInflammatory diseases of the bones often result in excessive release of inflammatory cytokines and impaired osteogenic differentiation. Tumor necrosis factor-α (TNF-α) is an important inflammatory cytokine in disease, and implicated in developing PANoptosis. Although TNF-α has captured much attention in PANoptosis, their relationship in osteogenic differentiation remains elusive. Therefore, it is necessary to explore how TNF-α inhibits osteogenic differentiation and the mechanism involved.
methodsRNA sequencing was used to sequence normal and TNF-α-treated cells and screen for differentially expressed 43 genes of PANotosis. PCR and Western blotting were performed to validate sequencing results consistent. The degree of osteoblast differentiation was determined by alkaline phosphatase and calcium ion quantification. The extent of cell death was evaluated by cell death staining, lactate dehydrogenase quantification, and propidium iodide staining.
resultsCalcium ion quantification, RUNX2 and ALP confirmed that osteogenic differentiation was inhibited, and related to the cell death increase. More importantly, scanning electron microscopy revealed that multiple PANotosis morphologies appeared in the same field of view. We also demonstrated that by interdict NLRP3, cells could be rescued from PANoptosis and the inhibition of osteogenic differentiation caused by TNF-α. Further, immunofluorescence and coimmunoprecipitation of several closely related proteins were performed to verify the possible presence of PANoptosome.
conclusionIn summary, inhibition PANoptosis may serve as a new therapeutic target for bone infection and may plays an important role in osteogenic differentiation and inflammatory cell death in bone infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.